- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04369417
Evaluation of a Resiliency Intervention for Siblings of Children With Autism Spectrum Disorder (ASD) (SibChat)
The proposed research has the following objectives:
Based off findings from the "Development of a Resiliency Program for Siblings of Children with Autism Spectrum Disorder" qualitative focus group study (protocol 2019P002284), the aim is to determine the feasibility and acceptability, of an 8-session Relaxation Response Resiliency (SibChat) program for siblings of children with ASD.
We primarily aim to test the preliminary effectiveness of a pilot waitlist controlled trial on improving resiliency and stress coping, This will be assessed by comparing Baseline-3 mo. scores on primary and secondary outcome measures between the Immediate and Waitlist control groups.
Among participants randomized to both conditions, we secondarily aim to investigate the extent of pre-post changes in primary and secondary outcomes. Among immediate condition group only, we also aim to assess whether end-of-treatment (3 mo. post enrollment) improvements will be sustained at 6-mo. post enrollment.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Massachusetts General Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 14-17 years (inclusive of ages 14 and 17)
- Being the sibling of at least one individual with ASD
- Access to internet or smart phone
- English speaking
Exclusion Criteria:
- Diagnosis of ASD
- Past year psychiatric hospitalization
There are no exclusion criteria with respect to ethnicity or socioeconomic status.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation factorielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Experimental: 3RP treatment
An adapted version of the Relaxation Response Resiliency Program (3RP) for siblings of children with ASD.
The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
|
Virtually delivered psycho-educational resiliency training program for teenage siblings of children with ASD.
|
Comparateur actif: Active Comparator: Waitlist control
An adapted version of the Relaxation Response Resiliency Program (3RP) for siblings of children with ASD.
The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
|
Virtually delivered psycho-educational resiliency training program for teenage siblings of children with ASD.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Feasibility assessed by the number participants enrolled.
Délai: 6 months
|
We will assess study feasibility based on number of participants enrolled in the study (target N=40)
|
6 months
|
Feasibility assessed by the number SibChat-3RP of sessions attended
Délai: 8 weeks
|
Whether youth attended at least 5 out of 8 total program sessions.
|
8 weeks
|
Feasibility assessed by the survey retention post intervention.
Délai: 6 months
|
Among participants randomized to both conditions, feasibility is assessed by the number of participants who completed the T2 and T3 surveys, 3 months and 6 months post baseline, respectively.
|
6 months
|
Acceptability assessed using the participant feedback survey
Délai: 3 months
|
The participant feedback survey is a questionnaire made up of likert scales and open ended questions designed to record acceptability of the SibChat-3RP program on topics including length of sessions, number of sessions, and virtual delivery.
|
3 months
|
Acceptability assessed by relaxation response adherence
Délai: 3 months
|
Among participants randomized to both conditions, relaxation response adherence is measured at T1, T2 and T3.
Relaxation response adherence is a 1-item likert scale that indicates how often participants practice relaxation response exercises.
Acceptability is determined based on whether participants indicate that they practice relaxation response exercises at least bimonthly 3 months post intervention.
|
3 months
|
Effectiveness of trial on improving stress coping ability (assessed using Measure of Current Status-A)
Délai: 3 months
|
Measure of Current Status-A is a questionnaire - the score on the questionnaire is used to indicate stress coping ability.
A change in score indicates a change in indicated stress coping ability.
Comparison of intervention and wait list control 3 months after baseline (T1).
|
3 months
|
Effectiveness of trial on improving resiliency (assessed using Current Experiences Scale)
Délai: 3 months
|
Current experiences Scale is a questionnaire.
Improved resiliency is measured base upon change in questionnaire score.
Comparison of intervention and wait list control 3 months after baseline (T1).
|
3 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Pre-post intervention changes as measured by change in primary outcome scores of resiliency and stress coping.
Délai: 3 months
|
Among participants randomized to both conditions, pre-post intervention changes in primary outcome scores of resiliency and stress coping will be assessed using the scores from the questionnaire (includes all primary outcome scores indicated above).
|
3 months
|
Sustained improvements in primary outcomes of resiliency and stress coping as measured by sustained change in primary outcome scores.
Délai: 3 months
|
Among immediate condition group only, assess whether end-of-treatment (3 mo.
post enrollment) improvements in primary outcome scores (resiliency and stress coping indicated above; collected using a questionnaire) will be sustained at 6-mo.
post enrollment.
|
3 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Karen A Kuhlthau, PhD, Massachusetts General Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2019P003218
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .